Early trial results suggest an experimental Alzheimer’s treatment targeting tau protein may slow cognitive decline, offering hope for future therapies and highlighting the importance of continued research participation.
Researchers at University College London and University College London Hospitals have reported encouraging early findings from a clinical trial of an experimental Alzheimer’s treatment that targets tau, a protein strongly linked to disease progression.
The phase I trial investigated the drug RI-AG03, which is designed to prevent tau proteins from clumping together and damaging brain cells. Unlike currently approved Alzheimer’s medicines that focus on amyloid plaques, this approach targets tau, which is more closely associated with worsening symptoms and cognitive decline.
The study involved 48 people with early Alzheimer’s disease who received either the experimental treatment or a placebo over a 12-week period. The trial was primarily designed to assess safety, but researchers also observed signs that participants receiving the drug experienced slower cognitive decline over the following year compared with those who received placebo. The findings are preliminary and the study was not large enough to prove effectiveness, but the results have been described as promising enough to justify larger trials. UCL News UCLH BRC
Scientists have long recognised that abnormal tau proteins accumulate inside brain cells in Alzheimer’s disease, forming tangles that disrupt communication between neurons and eventually lead to cell death. While amyloid-targeting treatments have recently begun to emerge, many researchers believe that therapies aimed at tau may be crucial for achieving greater benefits for patients.
Professor Catherine Mummery, consultant neurologist at the National Hospital for Neurology and Neurosurgery and the trial’s chief investigator, said the early findings were an important step forward:
“This is the first time we have seen a signal in humans that a treatment designed to stop tau aggregation may have an effect on cognitive decline. These are very early results and need to be confirmed in much larger studies, but they give us hope that targeting tau could become an important new approach for treating Alzheimer’s disease.”
The researchers emphasised that the treatment remains experimental and is not available outside clinical trials. Further studies involving many more participants will be needed to determine whether the drug can genuinely slow the progression of Alzheimer’s disease and how long any benefits might last.
The work was supported by the UCLH Biomedical Research Centre and forms part of a wider effort to develop new treatments for neurodegenerative diseases through early-phase clinical research. The trial also demonstrates the growing importance of research participation by people living with dementia and their families.
Alzheimer’s disease affects hundreds of thousands of people across the UK and remains the most common cause of dementia. Symptoms typically include memory problems, difficulties with language and reasoning, and increasing challenges with everyday activities. Although recent advances have led to the first disease-modifying treatments targeting amyloid, researchers continue to search for therapies that can provide greater and more sustained benefits.
Professor Mummery added that progress in Alzheimer’s research depends on collaboration between scientists, clinicians and volunteers:
“Every advance we make is only possible because people with Alzheimer’s disease and their families are willing to take part in research. Their contribution is helping us move towards treatments that may one day change the course of this disease.”
For patients and families affected by Alzheimer’s disease, the new findings should be viewed as a source of cautious optimism rather than a proven breakthrough. Nevertheless, they represent an encouraging development in the search for additional ways to slow the progression of a condition that currently has no cure.
For more information, see the original reports from UCL News and the UCLH Biomedical Research Centre.
Image: Wikimedia Commons